{"id":151793,"date":"2026-08-24T23:11:26","date_gmt":"2026-08-24T23:11:26","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/151793\/"},"modified":"2026-08-24T23:11:26","modified_gmt":"2026-08-24T23:11:26","slug":"lilly-novo-amp-up-glp-1-fight-with-new-weapon-against-copycats-3","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/151793\/","title":{"rendered":"Lilly, Novo Amp Up GLP-1 Fight With New Weapon Against Copycats"},"content":{"rendered":"<p>Eli Lilly &amp; Co. and Novo Nordisk A\/S are leveraging a fresh weapon in their crackdown against copycat versions of their blockbuster weight loss drugs.<\/p>\n<p>The two pharmaceutical giants over the last year have filed 10 cases against compounders and telehealth companies with BBB National Programs\u2019 National Advertising Division, a self-regulatory body providing dispute resolution over advertising claims. The non-government group has been around since 1971, <a href=\"https:\/\/bbbprograms.org\/media\/newsroom\/decisions\" rel=\"nofollow noopener\" target=\"_blank\">settling disagreements<\/a> over products from bathroom cleaners to infant formula \u2014 but the GLP-1 drugmakers turned to it relatively recently.<\/p>\n<p>It\u2019s another avenue in the aggressive fight to rein in unapproved versions of their powerful obesity and diabetes GLP-1 drugs, adding to a string of <a data-terminal-id=\"TFZYD4KGIFQN\" href=\"https:\/\/news.bloomberglaw.com\/health-law-and-business\/states-form-new-battleground-for-pharmas-fight-against-copycats\" rel=\"nofollow noopener\" target=\"_blank\">federal lawsuits<\/a> and cease-and-desist letters filed against copycats in the last two years. The latest endeavor has so far proven successful as compounders have voluntarily discontinued or modified disputed claims.<\/p>\n<p>The stakes are clear: Lilly\u2019s tirzepatide and Novo\u2019s semaglutide are among the only FDA-cleared GLP-1 drugs. Lilly\u2019s franchise reached $40 billion in sales, while Novo\u2019s products generated $35 billion last year.<\/p>\n<p>\u201cThey\u2019re using a lot of arsenals,\u201d said Alan Minsk, chair of the food and drug practice at Arnall Golden Gregory LLP. \u201cThese are big bucks for the companies and they\u2019re trying to use all of their tools that they\u2019ve got.\u201d <\/p>\n<p>The <a data-terminal-id=\"TFZYD4KGIFQN\" href=\"https:\/\/news.bloomberglaw.com\/health-law-and-business\/states-form-new-battleground-for-pharmas-fight-against-copycats\" rel=\"nofollow noopener\" target=\"_blank\">series of challenges<\/a> largely began after the FDA determined that branded GLP-1s are now available following a <a data-terminal-id=\"SOQYSET0AFB4\" href=\"https:\/\/news.bloomberglaw.com\/health-law-and-business\/lilly-weight-loss-drug-shortage-in-us-has-ended-fda-says\" rel=\"nofollow noopener\" target=\"_blank\">shortage period<\/a>, effectively prohibiting mass production of cheaper copies that have been used by at least a million patients. Still, compounders continue to make personalized versions. <\/p>\n<p> <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/08\/1787613086_823_.png\" data-alignment=\"center\" data-size=\"embedded\"\/> <\/p>\n<p>\u201cWe will continue to work with law enforcement and regulators to help address illegal activity,\u201d a Novo spokesperson said in an email, sharing the company has filed 130 federal lawsuits and five challenges with the NAD. \u201cNovo Nordisk views NAD challenges as an important forum to bring complaints against companies making false and misleading claims about unapproved compounded drugs.\u201d<\/p>\n<p>Lilly, which has also filed dozens of federal lawsuits and at least five cases with the NAD, similarly credited the division as \u201can independent authority whose mission is to build consumer trust in advertising.\u201d<\/p>\n<p>Each company challenged by Novo or Lilly did not respond to requests for comment.<\/p>\n<p>Speedier Pathway<\/p>\n<p>The forum has long served as a faster and more cost-effective process compared to litigation, which can drag on for years.<\/p>\n<p>Unlike legal proceedings, the burden is on the defendant, or the advertiser, to demonstrate it has a reasonable basis to make the claim at issue. The division assigns an attorney to review a case, confer with parties for a briefing period, and ultimately draft a decision or recommendation.<\/p>\n<p>The process, however, is voluntary. Companies can file a challenge, but an advertiser isn\u2019t required to participate in the case or follow recommendations. While the NAD doesn\u2019t hold any legal authority, it can escalate the matter to regulators such as the FDA, Federal Trade Commission, or state attorneys general for potential enforcement. It may also report the ad to social media platforms where it runs. <\/p>\n<p>\u201cIt\u2019s been interesting to see this case package come from the GLP-1 manufacturers,\u201d Phyllis Marcus, vice president of the NAD. \u201cThey present almost the full suite of advertising techniques. You\u2019ve got social media, you\u2019ve got influencers, you\u2019ve got health claims, you\u2019ve got one of the hottest drugs on the market.\u201d<\/p>\n<p>Advertisers can appeal decisions to a board of academics and brand representatives.<\/p>\n<p>\u201cThe options vary a lot in terms of cost, timeframe to a resolution, and effectiveness,\u201d said Ricardo Carvajal, a director at Hyman, Phelps &amp; McNamara P.C., representing advertisers. \u201cBut at the end of the day, we\u2019re talking about a matter of months to get to a final resolution in the form of an NAD case decision.\u201d<\/p>\n<p>Lilly\u2019s <a href=\"https:\/\/bbbprograms.org\/media\/newsroom\/decisions\/noom\" rel=\"nofollow noopener\" target=\"_blank\">latest challenge<\/a> targeted Noom Inc.\u2019s \u201cA Smaller Dose. A Smarter Start\u201d tagline for its compounded GLP-1s. The NAD determined the company failed to provide adequate support for its message. Noom disagreed with the conclusion but still agreed to drop or modify the claim.<\/p>\n<p>Novo\u2019s <a href=\"https:\/\/bbbprograms.org\/media\/newsroom\/decisions\/willow-health-ro\" rel=\"nofollow noopener\" target=\"_blank\">latest case<\/a> pressured Willow Health Services Inc. to permanently discontinue certain safety and efficacy claims for its compounded semaglutide. The move came after the NAD referred the matter to the FTC and state attorneys general when Willow failed to provide a statement indicating whether it would comply with recommendations.<\/p>\n<p>Seeking Enforcement<\/p>\n<p>The rise in challenges comes amid a lighter regulatory touch from the FDA.<\/p>\n<p>\u201cFDA is likely receiving many trade complaints,\u201d said Dara Katcher Levy, a director at Hyman, counseling companies on product communications. \u201cThat\u2019s probably why companies are now moving toward the NAD option of bringing their complaints. FDA\u2019s warning letters, at least in this space for the telehealth and compounders, have been very narrow.\u201d <\/p>\n<p>While compounded drug ads can\u2019t be false or misleading under federal laws, they still don\u2019t face the same kind of <a data-terminal-id=\"T446L9GQ1YQK\" href=\"https:\/\/news.bloomberglaw.com\/health-law-and-business\/fdas-deceptive-drug-ad-focus-leaves-telehealth-sites-guessing\" rel=\"nofollow noopener\" target=\"_blank\">government sign-off<\/a> as brand-name treatments. Still, the FDA has increasingly targeted them in the last year with more than <a data-terminal-id=\"T2GX8XGQ7KZU\" href=\"https:\/\/news.bloomberglaw.com\/health-law-and-business\/fda-signals-more-oversight-of-compounders-in-drug-ads-crackdown\" rel=\"nofollow noopener\" target=\"_blank\">100 warning letters<\/a> sent to companies regarding misbranded claims.<\/p>\n<p>But even with increased oversight, the FDA\u2019s warnings have largely focused on a limited set of claims such as active ingredients, branding, and product performance. <\/p>\n<p>\u201cThe enforcement has really been focused on what these websites shouldn\u2019t say, and that absolutely is needed,\u201d said Ashwin Chetty, a doctor of medicine candidate at Yale School of Medicine, who <a href=\"https:\/\/jamanetwork.com\/journals\/jama-health-forum\/fullarticle\/2829225\" rel=\"nofollow noopener\" target=\"_blank\">studied<\/a> compounded GLP-1 ads. \u201cBut there should also be some guidance and enforcement on what these websites should be saying as well.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly &amp; Co. and Novo Nordisk A\/S are leveraging a fresh weapon in their crackdown against copycat&hellip;\n","protected":false},"author":2,"featured_media":151794,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[272,3588,64656,2338,1446,360],"class_list":["post-151793","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-novo-nordisk","tag-online-advertising","tag-pharmaceutical-advertising","tag-settlements","tag-social-media","tag-telehealth"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117153017951771142","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/151793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=151793"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/151793\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/151794"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=151793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=151793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=151793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}